

determine whether a prospective contractor is responsible by obtaining information regarding financial and other capabilities of the prospective contractor.

## B. Annual Reporting Burden

Respondents: 2,200; annual responses: 2,200; average hours per response: 1; burden hours: 2,200.

*Copy of proposal:* A copy of this proposal may be obtained from the GSA Acquisition Policy Division (MVP), Room 4011, GSA Building, 1800 F Street NW, Washington, DC 20405, or by telephoning (202) 501-3822, or by faxing your request to (202) 501-3341.

Dated: April 15, 1998.

**Ida M. Ustad,**

*Deputy Associate Administrator for Acquisition Policy.*

[FR Doc. 98-10638 Filed 4-21-98; 8:45 am]

BILLING CODE 6820-61-M

## GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090-0200]

### Submission for OMB Review; Comment Request Entitled Sealed Bidding

**AGENCY:** Office of Acquisition Policy, GSA.

**ACTION:** Notice of request for public comments regarding reinstatement to a previously approved OMB clearance (3090-0200).

**SUMMARY:** Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the Office of Acquisition Policy has submitted to the Office of Management and Budget (OMB) a request to review and approve a reinstatement of a previously approved information collection requirement concerning Sealed Bidding.

**DATES:** Comment due date: June 22, 1998.

**FOR FURTHER INFORMATION CONTACT:** Al Matera, Office of GSA Acquisition Policy, (202) 501-1224.

**ADDRESSES:** Comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, should be submitted to: Edward Springer, GSA Desk Officer, Room 3235, NEOB, Washington, DC 20503, and to Marjorie Ashby, General Services Administration (MVP), 1800 F Street NW, Washington, DC 20405.

## SUPPLEMENTARY INFORMATION:

### A. Purpose

The GSA is requesting the Office of Management and Budget (OMB) to reinstate information collection, 3090-0200, Sealed Bidding. The information requested regarding an offeror's monthly production capability is needed to make progressive awards to ensure coverage of stock items.

### B. Annual Reporting Burden

Respondents: 20; annual responses: 20; average hours per response: .10; burden hours: 3.3.

*Copy of proposal:* A copy of this proposal may be obtained from the GSA Acquisition Policy Division (MVP), Room 4011, GSA Building, 1800 F Street NW, Washington, DC 20405, or by telephoning (202) 501-3822, or by faxing your request to (202) 501-3341.

Dated: April 15, 1998.

**Ida M. Ustad,**

*Deputy Associate Administrator for Acquisition Policy.*

[FR Doc. 98-10639 Filed 4-21-98; 8:45 am]

BILLING CODE 6820-61-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

#### Cynthia King, Bienville Medical Group

Based on an investigation conducted by ORI's Division of Research Investigations, ORI found that Ms. King, staff assistant, Bienville Medical Group, engaged in scientific misconduct in clinical research conducted as part of a multicenter clinical trial supported by a National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) contract. Ms. King falsified and/or fabricated data and information collected from patients for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) at the clinical site in Terry, Mississippi. ORI acknowledges Ms. King's cooperation and assistance in completing its investigation.

Ms. King has accepted the ORI finding and has entered into an Agreement with ORI in which she has voluntarily agreed, for the three (3) year period beginning April 6, 1998:

(1) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which Ms. King's participation is proposed or which uses her in any capacity on PHS supported research or that submits a report of PHS-funded research in which she is involved must concurrently submit a plan for supervision of her duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. King's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

No scientific publications were required to be corrected as part of this Agreement.

#### FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

**Chris B. Pascal,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 98-10660 Filed 4-21-98; 8:45 am]

BILLING CODE 4160-17-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

#### Patrina Lowe, Bienville Medical Group

Based on an investigation conducted by ORI's Division of Research Investigations, ORI found that Ms. Lowe, former staff member, Bienville Medical Group, engaged in scientific misconduct in clinical research conducted as part of a multicenter clinical trial supported by a National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) contract. Ms. Lowe falsified and/or fabricated data and information collected from patients for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) at the clinical site in Terry, Mississippi. ORI acknowledges Ms.